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ORIGINAL ARTICLE

Role of Myocardial Strain Imaging by
Echocardiography for the Early Detection of
Anthracyclines-Induced Cardiotoxicity
Reham Selmy Abo El Magd Rasheed*, Hatem Mohammed Fathy El Sokkary,
Mahmoud Zaki El Amrosy, Mohammed El Sayd El Setiha,
Mai Mohammed Abd EL Moneim Salama
a

Cardiology Department, Tanta University Hospital, El Gharbia, Egypt

Summary
Objective: To investigate the role of myocardial strain imaging by echocardiography is for detecting anthracyclineinduced cardiotoxicity early.
Patients and methods: Fifty patients had transthoracic echocardiogram before, during, and after taking anthracyclines.
GE Vivid E9 Ultrasound System was used for echocardiographic examination and myocardial strain imaging. All patients were assessed three times: on the ﬁrst visit, before starting anthracycline medication; on the second visit, three
months later; and on the third visit, six months later.
Results: Cardiotoxicity occurred in 4 patients at the end of the research. There was a statistically signiﬁcant association
between percentage change in global longitudinal strain (GLS) and ejection fraction (EF) at 3 months p < 0.001 and 6
months p < 0.001. Change in the GLS at 3 months and 6 months had a sensitivity and speciﬁcity of 100%, 95.65%, and
100%, 89.13% respectively. Using receiver operating characteristic curve (ROC) for change in GLS showed that Area
Under a Curve (AUC) ¼ 1.000, sensitivity, speciﬁcity, positive predictive value, and negative predictive value all equals
100%.
Conclusion: Strain echocardiographic examination using GLS is a good predictor for early detection of left ventricle
dysfunction caused by anthracyclines chemotherapy.
Keywords: Anthracyclines, Echocardiogram, Cardiotoxicity

1. Introduction

O

ver the last 20e30 years, the death rate among
cancer patients has reduced by 21% and 12%
in males and females, respectively, from 1991 [1].
Nonetheless,
cancer
therapy-induced
heart
toxicity (cardiotoxicity) has become a prominent
survivors' source of morbidity and mortality. Patients who acquire heart failure because of cancer
treatment have a death risk of up to 60% after two
years [2,3].

The most frequent deﬁnition of cardiotoxicity is a
5% decline in symptomatic individuals' LVEF from
baseline to LVEF <55% (or a 10% reduction in
asymptomatic people). In the early phases of cardiotoxicity, cardiac imaging has been utilized to
detect a reduction in LV function without signs or
symptoms of the heart toxicity [4e8].
Chemotherapeutic medications including anthracyclines act by disrupting cancer cells' genes and
preventing them from reproducing. Breast, gynecologic, sarcoma, and lymphoma are among the cancers
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treated with anthracyclines, particularly doxorubicin.
The negative effects of anthracycline treatment on the
cardiac muscle are well documented. Cardiotoxicity is
induced by cardiac myocyte necrosis and apoptosis,
after which myocardial ﬁbrosis occurs [9].
Cardiotoxicity must be carefully considered during treatment, with an emphasis on early detection
and intervention [2,3]. Although an endomyocardial
biopsy is the current gold standard for detecting
anthracycline-induced cardiomyopathy [10], It is
ineffective as a ﬁrst-line approach for detecting
cardiotoxicity or serial monitoring [11]. The measurement of LVSF by echocardiography is the
utmost popular non-invasive approach of monitoring myocardial toxicity, although it is insensitive
for early diagnosis of subclinical cardiac illness [12].
For evaluating cardiotoxicity, myocardial strain, or
the percent of myocardial thickening or distortion
during the cardiac cycle, LVEF is less sensitive than
strain rate [13,14]. These measurements can be used
to assess cardiac mechanics on a multidimensional
level (longitudinal, radial, and circumferential
function). The longitudinal strain appears to be the
most consistent, whereas the radial strain appears to
be the most variable, with the added beneﬁt of being
able to detect minor regional function defects that
do not affect global LVEF [15]. The global strain is
deﬁned as the average value of all the strain measurements. All strain parameters are impacted as
the disease progresses [14].
The goal of the study was to analyze how useful
myocardial strain imaging by echo is for detecting
Anthracyclines-induced cardiotoxicity early.

2. Materials
A prospective observational study was conducted
at Cardiology Department, Tanta University, from
September 2018 to February 2019 and included Fifty
patients who were planned to receive anthracyclines
chemotherapy were included in the study.
2.1. Study approval
2.1.1. Ethics
Permission to perform this study and use the
hospital facilities was acquired from Tanta University Research Ethics Committee, which is part of the
Faculty of Medicine, Quality Assurance Unit.
2.1.2. consent
All patients provided their informed written consent after a thorough explanation of the study's
beneﬁts and risks.
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Abbreviations list
abGLS
BC
ECG
echo
EF
GLS
DGLS
LV
LVEF
LVSF
STE

absolute reduction in GLS
Breast cancer
Electrocardiogram
echocardiogram
Ejection fraction
Global longitudinal strain
Percentage change in GLS
Left ventricle
Left ventricular ejection fraction
Left ventricular systolic function
Speckle tracking echocardiography

2.2. Inclusion criteria
All patients were presented with cancer (any type)
requiring anthracyclines chemotherapy, with baseline LVEF >55%.
2.3. Exclusion criteria
Pregnant or breastfeeding women, patients who
were receiving chemotherapeutic agents other than
anthracyclines, patients with baseline LVEF <55%,
patients with moderate to severe aortic or mitral
valve disease, as well as those with an unstable
cardiac condition such pericardial effusion. Also, the
poor image quality was excluded.

3. Methods
The following procedures were performed on
patients: Full history taking, Laboratory investigations, complete clinical examination, resting
12 leads ECG. Transthoracic echo to detect the
underlying cardiac lesion and to assess EF and
GLS. The GLS was calculated using apical views
(four, two, and three chambers). Myocardial
speckles were automatically traced on subsequent
frames by tracing the endocardial borders on an
end-systolic frame. Adequate tracking was veriﬁed
and, if necessary, manually adjusted. The average
of regional strains was used to calculate GLS. Between baseline and follow-up visits, the percent
change in GLS (DGLS) and absolute reduction in
GLS (abGLS) were computed. Two readers examined the LVEF and GLS data. The readers were
blinded to each other’s measures as well as the
patient visit number.
All patients were assessed three times: on the ﬁrst
visit, before starting anthracycline medication; on
the second visit, three months later; and on the third
visit, six months later.
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Table 1. Comparison between the three studied periods according to EF%.
EF%

Before (n ¼ 50)

3 months (n ¼ 50)

6 months (n ¼ 50)

F

p

Min. e Max.
Mean ± SD.
Median (IQR)
Sig. bet. periods

56.0e74.0
65.70 ± 4.88
66.50 (62.0e70.0)
p1 < 0.001*,p2 < 0.001*,p3

50.0e71.0
64.10 ± 5.46
65.0 (60.0e70.0)
¼ 0.445

48.0e72.0
63.64 ± 6.09
66.0 (60.0e68.0)

21.888*

<0.001*

Fr: Friedman test, Sig. bet. periods was done using Post Hoc Test (Dunn's).
IQR: Inter quartile range SD: Standard deviation.
p: p value for comparing between the studied periods.
p1: p value for comparing between before and 3 months.
p2: p value for comparing between before and 6 months.
p3: p value for comparing between 3 months and 6 months.
*: Statistically signiﬁcant at p  0.05.

3.1. Statistical analysis of the data

4. Results
4.1. Regarding the demographic data and risk
factors

The IBM SPSS software package version 20.0 was
used to analyze the data provided into the computer. The signiﬁcance of the acquired results was
determined at a 5% level.

There were 12 (24%) males and 38 (76%) females
in the study. The participants ranged in age from 20

Table 2. Comparison between the three studied periods according to GLS%.
GLS%

Before (n ¼ 50)

3 months (n ¼ 50)

Min. e Max.
Mean ± SD.
Median (IQR)
Sig. bet. periods

25.0e17.0
22.50e11.0
19.57 ± 1.66
18.20 ± 2.42
19.0 (-20.3e18.2)
18.30 (-19.8e17.5)
p1 < 0.001*,p2 < 0.001*,p3 ¼ 0.147

6 months (n ¼ 50)

Fr

p

22.0e7.40
17.84 ± 2.94
18.20 (-19.2e17.3)

71.344*

<0.001*

Fr: Friedman test, Sig. bet. periods was done using Post Hoc Test (Dunn's).
IQR: Inter quartile range SD: Standard deviation.
p: p value for comparing between the studied periods.
p1: p value for comparing between before and 3 months.
p2: p value for comparing between before and 6 months.
p3: p value for comparing between 3 months and 6 months.
*: Statistically signiﬁcant at p  0.05.
Table 3. Agreement (sensitivity, speciﬁcity and accuracy) for D GLS at 3 and 6 months.
EF 6 months

D GLS 3 months
Normal (<15)
Abnormal (15)
c2 (FEp)
D GLS 6 months
Normal (<15)
Abnormal (15)
c2 (FEp)

Sensitivity

Speciﬁcity

PPV

NPV

Accuracy

0.0
100.0

100.0

95.65

66.67

100.0

96.0

0.0
100.0

100.0

89.13

44.44

100.0

90.0

Normal (>53)
(n ¼ 46)

Abnormal
(53) (n ¼ 4)

No

No

%

44
95.7
2
4.3
31.884*(<0.001*)

0
4

41
89.1
5
10.9
19.807*(<0.001*)

0
4

%

c2: Chi square test FE: Fisher Exact.
p: p value for association between different categories.
*: Statistically signiﬁcant at p  0.05.
PPV: Positive predictive value.
NPV: Negative predictive value.

to 67 years old with a mean ± SD of 45.34 ± 12.11
years. Twelve patients (24%) had hypertension, ﬁve
patients had diabetes (10%), seven patients were
smokers (14%), ﬁve patients suffered from obesity
(10%); their body mass index (BMI) 30kg/m2. The
mean cumulative dose of anthracycline at the second visit was 203.50 ± 21.55 mg/m2 and at the third
visit was 423.64 ± 32.33 mg/m2.
The study subjects' oncological diagnosis revealed
that 35 of them had breast cancer (BC) (70%), 13

35

patients had lymphoma (26%), one patient had
sarcoma (2%), and one patient had leukemia (2%).
The study's patients had never had chemotherapy or
radiation before.
4.2. Two-Dimensional Echocardiographic
Examination
Using 2D-TTE, cardiotoxicity detected by signiﬁcant reduction in LVEF in 4 participants at the end
of the trial (Table 1).

Fig. 1. Female patient aged 36 years, not known to be diabetic, not hypertensive, non-smoker, overweight with BMI¼25 kg/m2, not known to be
cardiac, no thyroid or chest diseases, diagnosed as breast cancer. She was planned to receive doxorubicin. On the ﬁrst visit (V1): (a, b): baseline
echocardiography showed no signiﬁcant abnormal echo-doppler data, EF¼71% and GLS¼-22.5%. On the second visit (V2): she received 215 mg/m2
of doxorubicin, only complaining of loss of appetite, echocardiographic examination (c, d) showed: EF¼70% and GLS¼-21% with AbGLS¼1.5 and
DGLS¼6.7%. On the third visit (V3): the cumulative dose reached was 427 mg/m2, echocardiographic examination (e, f) showed: EF¼67% and
GLS¼-18.8%, AbGLS¼3.7, DGLS¼16.4% (Signiﬁcant reduction in GLS or subclinical cardiotoxicity). (a, c, e): 2D echocardiographic examination
for assessment of LVEF by M-mode. (B, D, F): Strain echocardiography examination to measure GLS showing Bull's eye.
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Using strain echo, as a baseline, GLS measurements were taken at the ﬁrst visit. The absolute
reduction in GLS (AbGLS) and the percent change
in GLS (DGLS) were calculated and tabulated during the second and third visits as shown in Table 2.
At the second visit, 6 patients had a signiﬁcant
reduction, and 3 more cases had a signiﬁcant
reduction at the third visit. By the end of six months,
nine patients had a signiﬁcant decrease in GLS (Fig.
1), and four of the nine patients had experienced
cardiotoxicity (Fig. 2). All of the four cases that
progressed to anthracycline-induced cardiotoxicity

revealed signiﬁcantly decreased GLS (GLS15%)
prior to the detection of signiﬁcant reduction in EF
evaluation by echo.
By Chi-square test, there was a statistically signiﬁcant association between D GLS and EF as D GLS
at 3 months’ values were c2 ¼ 31.884 p < 0.001 (pvalue for the association between different categories and statistically signiﬁcant at p  0.05) and D
GLS at 6 months values were c2 ¼ 19.807 p < 0.001.
Calculation of sensitivity and speciﬁcity of D
GLS at 3 and 6 months showed sensitivity and
speciﬁcity of 100%, 95.6%, and 100%, 89.13%

Fig. 2. Male patient aged 58 years, known to be hypertensive and smoker, not known to be diabetic or cardiac before, he denied having any thyroid or
chest problems, He had average BMI¼23kg/m2 diagnosed as lymphoma. He was planned to receive doxorubicin. On the ﬁrst visit (V1): (a, b): baseline
echocardiography showed no signiﬁcant abnormal echo-doppler data, EF¼62%, and GLS¼-18.2%. On the second visit (V2): He received a cumulative dose of 276 mg/m2, no complaint, Echocardiographic examination (c, d) showed: EF¼58%, GLS¼-12%, AbGLS¼ 6.2 and DGLS¼34%
(Subclinical cardiotoxicity). On the third visit (V3): Cumulative dose of doxorubicin¼ 457mg/m2, complaining of dyspnea grade III, echocardiographic examination (e, f) showed: , Ef¼53%, GLS¼-11.6%, AbGLS¼6.6 and DGLS¼36.2% (Cardiotoxicity occurred). (a, c, e): 2D echocardiographic examination for assessment of LVEF by M-mode. (B, D, F): Strain echocardiography examination to measure GLS showing Bull's eye.

Fig. 3. ROC curve for D GLS to diagnose abnormal EF (n¼ 4).

respectively, suggesting that D GLS is a good
predictor to diagnose LV affection by anthracyclines (Table 3).
Using receiver operating curve for D GLS before
diagnosing abnormal EF (Fig. 3) showed that area
under a curve ¼ 1.000, sensitivity, speciﬁcity, positive predictive value, and negative predictive value
all equals 100% (Table 4), proving the high efﬁciency
of D GLS to predict Anthracyclines-induced
cardiotoxicity.

5. Discussion
The use of 2D speckle tracking echo to measure
myocardial strain has proven to be a sensitive
technique for measuring ventricular function in
patients with early myocardial illness [16].
The current study aimed to evaluate the myocardial strain imaging role by echo using GLS (GLS) in
the early detection of anthracyclines-induced
cardiotoxicity.
A total of 50 adult patients were included in the
current study, with 12 males (24%) and 38 females
(76%). In this study age range 20e67 years; mean
age 45.34 years ± 12.11. Extreme older or younger
age (<18 and >65 years) is considered as a risk
factor.

In agreement with McGowan et al. [17], who reported that Cardiotoxicity develops over time based
on the age of the patient at the time of exposure and
the chemotherapy drug's class effect, with childhood
cancer survivors facing an exponentially increasing
risk of cardiovascular problems. Cardiovascular risk
in elderly, on the other hand, appears sooner and is
depending on the frequency of classic cardiac risk
factors that coexist, particularly hypertension.
In the current study, twelve patients (24%) had
hypertension; ﬁve patients (10%) had diabetes;
seven patients (14%) were smokers; and ﬁve patients suffered from obesity (10%) (their BMI
30kg/m2). The mean cumulative dose of anthracycline at the second visit was 203.50 ± 21.55 mg/
m2 and at the third visit was 423.64 ± 32.33 mg/
m2.
This comes in agreement with a study by Ryberg
et al. [18], who found that patients with risk factors
for heart disease (such as obstructive pulmonary
disease, hyperthyroidism, hypertension, diabetes,
and obesity) had a three-fold higher incidence of
toxicity to the heart, according to a 1097 BC patients'
competing risks analysis. Also, Swain et al. [19],
retrospective analysis showed that When the cumulative dose of doxorubicin approached 400 mg/
m2, the risk of congestive heart failure was 2.25 fold
higher in patients above 65 years old than in patients below 65 years old. Also, this study results
agreed with Dogru et al. [20], in research that
comprised 35 BC and 15 lymphoma patients who
received anthracycline-based chemotherapy, the
lymphoma cohort had signiﬁcantly reduced EF and
fractional shortening levels. They discovered a link
between anthracycline dosage and the development
of preclinical heart failure. On the contrary Gripp
et al. [21], reported no relation between cardiotoxicity and the conventional risk factors.
In this study, all of the four cases that progressed
to anthracycline-induced cardiotoxicity revealed
signiﬁcantly decreased GLS (GLS15%) prior to the
detection of signiﬁcant reduction in EF evaluation
by echo, indicating that GLS is a good and early
predictor of cardiotoxicity.
Similarly, Tang et al. [22] study provided a valuable insight into the value of 2D-speckle tracking

Table 4. Agreement (sensitivity, speciﬁcity) for D GLS to diagnose abnormal EF (n ¼ 4).
D GLS 3 months
D GLS 6 months

AUC

p

95% C.I

Cut off

Sensitivity

Speciﬁcity

PPV

NPV

1.000
1.000

<0.001*
<0.001*

1.0e1.0
1.0e1.0

>23
>28.7

100.0
100.0

100.0
100.0

100.0
100.0

100.0
100.0

AUC: Area Under a Curve: p value: Probability value.
CI: Conﬁdence Intervals.
NPV: Negative predictive value: PPV: Positive predictive value.
*: Statistically signiﬁcant at p  0.05.
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echo in the earlier diagnosis of cardiotoxicity caused
by anthracycline treatment. Early worsening of LV
global longitudinal and circumferential strain is
caused by anthracycline therapy. In cancer patients,
early changes in the GLS appear to be a good predictor of ventricular dysfunction. Also, Boyd et al.
[23] demonstrated that GLS is more sensitive in
detecting LV systolic subclinical impairment in the
early stages of anthracycline therapy.
Also, in agreement with Santoro et al. [24], 2D
GLS is superior to standard echo and presents a
good practicability.
Also, Zito et al. [25], Dogru et al. [20], D Mohty
et al. [26] and Laufer-Perl et al. [27] Poterucha et al.
[28] and Kang et al. [29], concluded that the use of
the use of GLS on a regular basis during treatment
could lead to an early detection of cardiotoxicity.
This also with Negishi et al. [3] A study involved
159 people who started using anthracyclines, trastuzumab, or their combination as an aspect of their
cancer treatment. The ﬁndings demonstrate that
GLS could be utilized to identify cardiac performance deterioration in patients treated with
anthracyclines, trastuzumab, or both.
Also, we agreed with a systematic review and
meta-analysis done by Oikonomou et al. [30], the
study comprised 1782 patients with cancer, such as
BC, hematologic tumors, or sarcomas, who
received anthracyclines with or without trastuzumab in 21 studies. Concluded that Deformation
analysis using GLS can be utilized to detect early
stages of subclinical ventricular dysfunction among
cancer patients who are receiving possibly cardiotoxic treatment before progression to chemotherapy-induced cardiotoxicity. The predictive and
discriminating performance of an active treatment
absolute GLS value or a relative change from
baseline seems to be comparable. GLS is now
recommended for patients with hematological and
solid tumors who are being cured with regimens
based on anthracyclines combined or not combined trastuzumab.
This also in the same line with Gripp et al. [21] in a
prospective and observational study of consecutive
cases diagnosed with BC Having no history of
anticancer therapy and no ventricular dysfunction,
who received anthracycline and/or trastuzumab
treatment. The study revealed that the LV GLS was
a strong indicator of cardiotoxicity, with a high
sensitivity for early detection.
On the other hand, Thavendiranathan et al.
[31] stated that reduced myocardial distortion
variables on echo are a marker of subclinical
myocardial alterations caused by cancer treatment and occur prior to any LVEF decline as

measured by standard 2D echo. Notably, early
decrease in cardiac distortion seems to predict
the occurrence of later cardiac toxicity, and the
most reliable indicator being GLS assessed by
speckle tracking echo (STE). STE is utilized to
predict cardiac toxicity using GLS change
criteria ranging from 10% to 15%. The low
occurrence of cardiotoxicity in the individuals
tested probably explains why these thresholds
have a stronger negative predictive value than
positive predictive value. Unfortunately, whereas
distortion measures tend to discover preclinical
myocardial alterations in survivors, their utility
in forecasting LV dysfunction or failure of the
heart muscle is uncertain.
5.1. Study Limitations
Our follow up period is relatively short.

6. Conclusion
The present study concluded that strain echocardiographic examination using GLS (GLS) is an
excellent predictor for early diagnosis of left ventricular impairment caused by anthracycline treatment because GLS values were signiﬁcantly
reduced (DGLS 15%) in all cases before progression to anthracyclines-induced cardiotoxicity (signiﬁcant reduction in EF values).
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